No Record Found
No Record Found
Sector
HealthcareOpen
₹417.6Prev. Close
₹415.4Turnover(Lac.)
₹2,635.85Day's High
₹423.85Day's Low
₹415.452 Week's High
₹728.652 Week's Low
₹380Book Value
₹116.55Face Value
₹10Mkt Cap (₹ Cr.)
16,968.23P/E
46.53EPS
8.93Divi. Yield
0.323 Apr 2025
12:00 AM
AGM
Announcement Date: 23 Apr, 2025
18 May 2026
12:00 AM
Board Meeting
Agenda : Audited Result
29 Apr 2026
12:00 AM
Dividend
Dividend Amount: 1.25
Record Date: 26 Jun, 2026
The outcome of the inspection has been classified as “Voluntary Action Indicated” or VAI.
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 402.9 | 402.5 | 402 | 401.4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,300.9 | 4,236.4 | 3,789.5 | 3,217.5 |
Net Worth | 4,703.8 | 4,638.9 | 4,191.5 | 3,618.9 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 2,601.4 | 2,179.4 | 2,011.9 | 1,423.1 |
yoy growth (%) | 19.36 | 8.32 | 41.37 | 18.5 |
Raw materials | -749 | -526.5 | -519.4 | -381.7 |
As % of sales | 28.79 | 24.15 | 25.81 | 26.82 |
Employee costs | -697.8 | -641.5 | -572.2 | -376.9 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 512.4 | 432.4 | 444.4 | 372.1 |
Depreciation | -309.7 | -274.5 | -219.3 | -131.4 |
Tax paid | -87.9 | -63.7 | -104.2 | -67 |
Working capital | -34.39 | 497.9 | -955.5 | 480.2 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.36 | 8.32 | 41.37 | 18.5 |
Op profit growth | 18.41 | 8.64 | 57.92 | 1.5 |
EBIT growth | 16.6 | -3.94 | 21.32 | 8.46 |
Net profit growth | -2.45 | -1.89 | 34.87 | 6.19 |
| Particulars (Rupees in Crores.) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|---|
Gross Sales | 3,738.7 | 3,642.4 | 3,488.6 | 3,192.9 | 2,604.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,738.7 | 3,642.4 | 3,488.6 | 3,192.9 | 2,604.2 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 70.7 | 103.8 | 90.6 | 70.9 | 52.8 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Apollo Hospitals Enterprise Ltd APOLLOHOSP | 8,841 | 84.69 | 1,27,148.05 | 382.4 | 0.23 | 2,438.5 | 692.92 |
Max Healthcare Institute Ltd MAXHEALTH | 1,108.1 | 146.98 | 1,07,144.41 | 203.21 | 0.18 | 732.9 | 91.86 |
Fortis Healthcare Ltd FORTIS | 968 | 352.41 | 71,834.27 | 24.98 | 0.11 | 460.73 | 122.24 |
Aster DM Healthcare Ltd ASTERDM | 808.9 | 127.46 | 41,804.6 | 27.46 | 0.37 | 655.1 | 83.23 |
Narayana Hrudayalaya Ltd NH | 2,027.3 | 75.62 | 40,644.3 | 202.13 | 0.23 | 1,044.05 | 127.1 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Kiran Mazumdar Shaw
Managing Director & CEO
Peter John Bains
Non-Exec & Non-Independent Dir
Catherine Patricia Rosenberg
Non-Exec & Non-Independent Dir
Vinita Bali
Independent Non Exe. Director
Kush Parmar
Lead Independent Non Executive Director
Sharmila Karve
Independent Non Exe. Director
Nilanjan Roy
Independent Non Exe. Director
Manja Boerman
Independent Non Exe. Director
Sanjaya Singh
Independent Non Exe. Director
Suresh Narayanan
Independent Director
Arun Suresh Chandavarkar
Company Sec. & Compli. Officer
Chethan Yogesh
Independent Director
Vijaya Chandru
Biocon SEZ Biocon Park,
Plot No 2 & 3 Bommasandra Inds,
Karnataka - 560099
Tel: 91-80-68915000/67758781
Website: http://www.syngeneintl.com
Email: investor@syngeneintl.com; Mayank.Verma@syngeneintl
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@karvy.com
Summary
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and ...
Read More
Reports by Syngene International Ltd
What is the Syngene International Ltd share price today?
What is the Market Cap of Syngene International Ltd?
What is the PE and PB ratio of Syngene International Ltd?
What is the 52 Week High and Low of Syngene International Ltd?
What is the CAGR of Syngene International Ltd?
What is the shareholding pattern of Syngene International Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
